Drugs that contain Zoledronic Acid
1. List of Reclast drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8052987 | NOVARTIS | Method of administering bisphosphonates |
Oct, 2023
(4 months from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(4 years from now) | |
|
US7932241 (Pediatric) | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(5 years from now) | |
Market Authorisation Date: 16 April, 2007
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis
Dosage: INJECTABLE;INTRAVENOUS
RECLAST family patents
5
United States
5
European Union
3
Japan
3
Australia
2
Canada
2
Slovenia
2
Korea, Republic of
2
Brazil
2
Taiwan
2
China
2
Denmark
2
Spain
2
New Zealand
2
Norway
2
South Africa
2
Russia
2
Israel
1
Slovakia
1
Poland
1
Luxembourg
1
Hong Kong
1
Iceland
1
Morocco
1
Germany
1
Cyprus
1
Czech Republic
1
Malaysia
1
Argentina
1
Hungary
1
Mexico
1
Colombia
1
Ecuador
1
Austria
1
Portugal
1
Tunisia
1
Peru
2. List of Zometa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(1 year, 11 months from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(2 years from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(4 years from now) | |
Market Authorisation Date: 20 August, 2001
Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy
Dosage: INJECTABLE;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic